NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.

Terms of the deal were not revealed, but the companies said the acquisition is anticipated to be completed during the next six months, contingent on the completion of due diligence and other conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.